The promise of GLP-1s depends on affordability

These anti-obesity drugs cost hundreds of dollars monthly if you pay cash. Without insurance coverage, access becomes a privilege for higher-income people, not those who need them most.

Coverage was expanding rapidly until recently

As of twenty twenty-six, roughly two thirds of private employer plans covering half of Americans were covering G L P one medications for weight loss.

Now employers are suddenly pulling back

Private plans are dropping G L P one coverage. At least ten percent of employer plans currently covering these drugs say they are likely to discontinue coverage in twenty twenty-seven.

Major brands are cutting coverage

PepsiCo, Starbucks and Lowe's are among the biggest US brands reportedly eliminating or reducing their G L P one coverage. A Mercer survey found six percent of large employers had dropped coverage in twenty twenty-six.

The reason is simple: cost

The drugs carry a high net price tag of six hundred dollars or more for a thirty day supply. Potential demand is high: two in every five American adults have obesity.

Rising costs force difficult choices

When many people take expensive medication at once, employer insurance premiums rise. Premiums are projected to grow by five to thirteen percent due to G L P one costs, with workers bearing the burden.

Employers are limiting access in multiple ways

According to Mercer, twenty-seven percent of large US employers instituted some kind of utilization controls for G L P one drugs over the past year or plan to next year.

Workers are devastated by the changes

One person on Reddit about Cigna's plans to drop G L P one coverage said they are looking at at least three hundred dollars for one month's supply at cash prices.

“I'm completely screwed”

Another worker lost a health breakthrough

A Starbucks employee said they were devastated by the decision to stop covering G L P one drugs.

“I'm devastated”

Short-term costs outweigh long-term benefits

An analysis by Blue Cross Blue Shield Kansas found covering G L P ones for weight loss increased average employee health costs by seven thousand dollars in the first year and another four thousand two…

No obesity improvements appeared quickly

The Blue Cross Blue Shield Kansas analysis found no decreases in obesity related medical events in the first two years.

The structural flaw in American healthcare

For working age adults, insurance depends on your job. People no longer stay at the same job for decades, so employers lack incentive to invest in long term health but have strong incentive to minimize…

Dan Sacks explains the mismatch

Dan Sacks, a healthcare economist at the University of Wisconsin Madison, said an employer or insurer making coverage decisions does not necessarily care if they are saving Medicare money.

“An employer or an insurer making coverage decisions doesn't necessarily care if they're saving Medicare money”

Generic versions are years away

Generic semaglutide will not be available in the US until at least twenty thirty-one. For some versions, generic competitors will not debut until the twenty forty-s.

Government action faces obstacles

The federal government's negotiating authority only covers Medicare, not the private plans dropping coverage. Serious healthcare reform is probably off the table until at least twenty twenty-eight.

The underlying problem demands attention

A patchwork method of insuring people that privileges short term cost cutting over long term health is not a real healthcare system. The US may need to look seriously at this underlying problem.